Oruka Therapeutics, Inc.

As of June 30, 2026, Oruka Therapeutics, Inc. carries a market capitalization of 5.10B, placing it among publicly traded companies globally. Its enterprise value stands at 4.34B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Oruka Therapeutics, Inc.'s next confirmed earnings release is scheduled for November 18, 2026.

As of June 30, 2026, Oruka Therapeutics, Inc. has 61.07M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Oruka Therapeutics, Inc. maintains a current ratio of 38.51, meaning it holds 38.5x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Oruka Therapeutics, Inc. posted a negative return on equity (ROE) of -18.30, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -17.76, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 58.00, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Oruka Therapeutics, Inc.'s stock has gained approximately 215.22% over the past 52 weeks. The 50-day moving average sits at 78.97, while the 200-day moving average is 59.03.

Over the twelve months ended June 30, 2026, Oruka Therapeutics, Inc. generated - - in revenue and converted that into -116.32M in net income, yielding earnings per share of -2.14. EBITDA reached -71.84M, while operating income came in at -135.74M.

As of June 30, 2026, Oruka Therapeutics, Inc. holds 764.63M in cash and equivalents against 2.23M in total debt, resulting in a net debt position of -234.99M. Total book value stands at 973.00M, with working capital of 754.15M providing operational flexibility.

Oruka Therapeutics, Inc. produced -88.33M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -205,695.50 in capital expenditures, free cash flow totaled -88.54M - equivalent to -1.63 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -1.96: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -15.00, meaning Oruka Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Oruka Therapeutics, Inc.'s most recent stock split took place on September 3, 2024 with a 12:1 split ratio.

As of June 30, 2026, Oruka Therapeutics, Inc. has an Altman Z-Score of 125.98, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.